WKWon Shik Kim

Won Shik Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Won Shik Kim has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Beom Jae Lee

    Division of Gastroenterology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, 148, Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea

    11 shared publications
  • Moon Kyung Joo

    Division of Gastroenterology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, 148, Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea

    11 shared publications
  • Jong-Jae Park

    Division of Gastroenterology, Department of Internal Medicine, Korea University Guro Hospital Korea University College of Medicine Seoul South Korea

    8 shared publications
  • Seung Han Kim

    Division of Gastroenterology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, 148, Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea

    7 shared publications
  • Hoon Jai Chun

    Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea

    5 shared publications
  • Ah Young Yoo

    Division of Gastroenterology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, 148, Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea

    4 shared publications

Latest Publications

  • Open Access

    Long-Term Surveillance After Curative Endoscopic Submucosal Dissection for Early Gastric Cancer: Distinct Clinicopathologic Characteristics of Early and Late Metachronous Neoplasia

    by Moon Kyung Joo, Seung Han Kim, Won Shik Kim, Beom Jae Lee

    Background: Endoscopic submucosal dissection (ESD) is an established treatment for early gastric cancer (EGC) meeting curative resection criteria. We examined clinicopathologic characteristics associated with early and late metachronous neoplasia after curative ESD. Methods: We retrospectively analyzed 185 patients who developed metachronous neoplasia among 1200 patients who underwent curative ESD for EGC. Metachronous neoplasia detected within 60 months was classified as early, and late if it is detected after 60 months. Results: Of the 185 patients with metachronous neoplasia (15.4%), 116 (62.7%) had early and 69 (37.3%) had late metachronous neoplasia; 102 developed cancer and 83 developed adenoma only. Undifferentiated histology of the index lesion was associated with late metachronous neoplasia overall (adjusted odds ratio [OR], 10.73; 95% confidence interval [CI], 1.27–90.35; p = 0.029). In the adenoma subgroup, undifferentiated histology occurred exclusively in patients with late metachronous adenoma (11.1% vs. 0%; p = 0.032), but its adjusted effect could not be estimated because of complete separation. Younger age was associated with late metachronous adenoma (adjusted OR per year, 0.937; 95% CI, 0.881–0.997; p = 0.040). In the cancer subgroup, serum triglyceride was associated with late metachronous cancer in univariable analysis (OR per 10 mg/dL, 1.064; 95% CI, 1.004–1.128; p = 0.036), but not after multivariable adjustment (p = 0.101). Conclusions: More than one-third of metachronous neoplasia were detected beyond five years after curative ESD. Undifferentiated histology was associated with late metachronous neoplasia overall and in the adenoma subgroup, although the latter association could not be adjusted. These findings warrant validation in larger cohorts.

  • Open Access

    The present and future of fecal microbiota transplantation

    by Won Shik Kim, Beom Jae Lee

    Purpose: Fecal microbiota transplantation (FMT) has emerged as one of the most effective interventions for restoring gut microbial balance through the reintroduction of a healthy donor microbiome. The established clinical indication for FMT currently remains limited to recurrent Clostridioides difficile infection (rCDI). This review aims to summarize the current understanding, evidence-based recommendations, and future perspectives regarding the clinical application of FMT.Current concepts: The 2024 American Gastroenterological Association guideline conditionally recommends microbiota-based therapies for adults with rCDI after completion of standard antibiotic treatment and suggests that conventional FMT may be considered in mildly to moderately immunocompromised patients. In contrast, its use is discouraged in severely immunocompromised individuals, and not recommended for conditions such as inflammatory bowel disease or irritable bowel syndrome because of insufficient evidence. Increasing evidence implicates the gut microbiota in the pathogenesis of various diseases, including neurologic and metabolic disorders. In parallel, advances in standardized preparations and the development of next-generation microbiota-based therapeutics underscore the broader therapeutic potential of FMT. However, outside the context of rCDI, both clinical effectiveness and long-term safety remain uncertain, and substantial challenges persist with respect to donor selection, product standardization, and procedural consistency.Discussion and conclusion: With an improved understanding of the mechanisms underlying dysbiosis and the accumulation of validated safety data, microbiota-based therapies are expected to evolve into additional therapeutic options for a variety of diseases. However, at present, clinical use should remain restricted to C. difficile infection, particularly rCDI, and should be limited to clinical settings supported by evidence-based guidelines.

  • Open Access

    Advancements in endoscopic resection of subepithelial tumors: toward safer, recurrence-free techniques

    by Won Shik Kim, Moon Kyung Joo

    Advancements in endoscopic resection of subepithelial tumors: toward safer, recurrence-free techniques


  • Balloon-assisted enteroscopy in the management of adult small-bowel intussusception: a comparative analysis of with and without double-balloon enteroscopy

    by Won Shik Kim, Beom Jae Lee, Moon Kyung Joo, Seung Han Kim, Jong-Jae Park

    Background Adult small-bowel intussusception (ASI) is a rare condition with pathological etiologies in most patients. Previously, surgical intervention was the primary treatment modality; however, the introduction of balloon-assisted enteroscopy (BAE) has allowed preoperative BAE in some cases to confirm the leading point, thereby guiding management and reducing surgical need. In this study, we investigated whether the introduction of BAE has altered the diagnostic and therapeutic strategies for ASI by retrospectively analyzing and comparing the clinicopathological features of patients before and after its introduction. Methods Fifty-three patients with ASI, initially diagnosed via abdominal computed tomography scanning at Korea University Guro Hospital from 2000 to 2023, were included in our study. Patients were grouped based on double-balloon enteroscopy (DBE) usage, and clinicopathological outcomes were compared retrospectively. Results Of the 53 patients, 38 (71.7%) had enteroenteric-type intussusception and 15 (28.3%) had enterocolic-type intussusception. Among the patients with enteroenteric-type intussusception, 15.8% had a malignant cause, whereas in the enterocolic type, 60% had a malignant cause (p = 0.001). Of 38 patients with enteroenteric ASI, 15 (39.5%) underwent preoperative DBE. The surgical resection rate was significantly lower in the DBE group (40%) than in the non-DBE group (73.9%) (p = 0.037). Pathological diagnoses of patients who underwent surgical resection without preoperative DBE revealed 17.6% malignancies and 82.4% benign causes, including idiopathic intussusception (four cases) and Peutz–Jeghers syndrome (two cases). No morbidity, mortality, or recurrence was observed. Conclusion Preoperative BAE is a valuable diagnostic and therapeutic modality for ASI, particularly in cases of low-grade small-bowel obstruction, reducing surgical resection rates in most ASI cases. The introduction of the BAE has significantly improved ASI management, achieving high successful reduction rates and few surgical interventions. BAE should be considered a first-line diagnostic and therapeutic tool for ASI management.

  • Open Access

    Recurrent Non-Variceal Upper Gastrointestinal Bleeding among Patients Receiving Dual Antiplatelet Therapy

    by Ah Young Yoo, Moon Kyung Joo, Jong-Jae Park, Beom Jae Lee, Seung Han Kim, Won Shik Kim, Hoon Jai Chun

    Background: Patients undergoing dual antiplatelet therapy (DAPT) may experience recurrent gastrointestinal bleeding (GIB). We investigated the clinical characteristics and risk factors for recurrent non-variceal upper gastrointestinal bleeding (NVUGIB) in patients who had experienced NVUGIB while receiving DAPT. Methods: We enrolled patients diagnosed with NVUGIB while receiving DAPT between 2006 and 2020. Definite bleeding was confirmed by esophagogastroduodenoscopy in all NVUGIB patients. Results: A total of 124 patients were diagnosed with NVUGIB while receiving DAPT. They were predominantly male (n = 103, 83.1%), bleeding mostly from the stomach (n = 94, 75.8%) and had peptic ulcers (n = 72, 58.1%). After the successful hemostasis of NVUGIB, 36 patients (29.0%) experienced at least one episode of recurrent upper GIB, 19 patients (15.3%) died, and 7 (5.6%) patients had a bleeding-related death. Multivariate analysis showed that age was a significant factor for re-bleeding (odds ratio [OR], 1.050; 95% confidence interval [CI]: 1.001–1.102; p-value: 0.047), all-cause mortality (OR, 1.096; 95% CI: 1.020–1.178, p = 0.013), and re-bleeding-related mortality (OR, 1.187; 95% CI: 1.032–1.364, p-value: 0.016). In Kaplan–Meier analysis, the cumulative probabilities of re-bleeding, death, and bleeding-related death were significantly higher in patients aged 70 and older (p = 0.008, <0.001, and 0.009, respectively). Conclusions: Clinicians should be cautious about re-bleeding and mortality in elderly patients who experience NVUGIB while receiving DAPT.


  • Open Access

    Re-bleeding and all-cause mortality risk in non-variceal upper gastrointestinal bleeding: focusing on patients receiving oral anticoagulant therapy

    by Won Shik Kim, Seung Han Kim, Moon Kyung Joo, Jong-Jae Park, Beom Jae Lee, Hoon Jai Chun

    Non-variceal upper gastrointestinal bleeding (NVUGIB) in patients receiving oral anticoagulants (OACs) may be fatal; however, little is known about re-bleeding and all-cause mortality after successful hemostasis. We investigated the clinical characteristics and risk factors for re-bleeding and death after successful hemostasis. Patients receiving OACs and diagnosed with NVUGIB between 2007 and 2021 were enrolled. All NVUGIB incidents were confirmed if definite bleeding in the upper gastrointestinal tract was detected via esophagogastroduodenoscopy. A total of 132 patients receiving OACs were diagnosed with NVUGIB. Males were the majority (72, 54.5%), and bleeding was detected mostly in the stomach (99, 75%) and was most often due to peptic ulcers (PU) (88, 66.7%). After successful hemostasis of index NVUGIB, 40 patients (30.3%) experienced re-bleeding. Among them, 15 (37.5%) died, and among those, 3 (2.3%) were related to re-bleeding. Multivariate analysis revealed that duodenal bleeding (odds ratio [OR]: 3.305; 95% confidence interval [CI]: 1.152-9.479, p = 0.026) and Charlson comorbidity index score (CCI) (OR: 1.22; 95% CI: 1.052–1.419, p = 0.009) were significant risk factors for re-bleeding. Index albumin levels (OR: 0.134; 95% CI: 0.035–0.506, p = 0.003), previous PU or upper gastrointestinal bleeding (UGIB) history (OR: 4.626; 95% CI: 1.375–15.567, p = 0.013), and CCI (OR: 1.293; 95% CI: 1.058–1.581, p = 0.012) were related all-cause mortality. CCI and duodenal bleeding are risk factors for re-bleeding in patients with NVUGIB who were receiving OACs, while low index albumin levels and previous PU and UGIB history are associated with all-cause mortality.


  • Open Access

    Recurrent Non-variceal Upper Gastrointestinal Bleeding among Patients Receiving Dual Antiplatelet Therapy

    by Ah Young Yoo, Moon Kyung Joo, Jong-Jae Park, Beom Jae Lee, Seung Han Kim, Won Shik Kim, Hoon Jai Chun

    Background: Patients undergoing dual antiplatelet therapy (DAPT) may experience recurrent gastrointestinal bleeding (GIB). We investigated the clinical characteristics and risk factors for recurrent non-variceal upper gastrointestinal bleeding (NVUGIB) in patients who had experienced NVUGIB during receiving DAPT. Methods: We enrolled patients diagnosed with NVUGIB during receiving DAPT between 2006 and 2020. Definite bleeding was confirmed by esophagogastroduodenoscopy in all NVUGIB patients. Results: A total of 124 patients were diagnosed with NVUGIB during receiving DAPT. Male was predominant (n = 103, 83.1%), bleeding mostly from the stomach (n = 94, 75.8%) and peptic ulcers (n = 72, 58.1%). After successful hemostasis of NVUGIB, 36 patients (29.0%) experienced at least one episode of recurrent upper GIB, 19 patients (15.3%) died, and 7 (5.6%) patients had a bleeding-related death. Multivariate analysis showed that age was a significant factor for re-bleeding (odds ratio [OR],1.050; 95% confidence interval [CI]:1.001-1.102, P-value:0.047), all-cause mortality (OR,1.096; 95% CI:1.020-1.178, P=0.013), and re-bleeding related mortality (OR,1.187; 95% CI:1.032-1.364, P-value:0.016). In Kaplan-Meier analysis, the cumulative probabilities of re-bleeding, death, and bleeding-related death were significantly higher in patients aged 70 and older (P=0.008, <0.001, and 0.009, respectively). Conclusion: Clinicians should be cautious about re-bleeding and mortality when elderly patients who experienced NVUGIB during receiving DAPT.Keywords: dual antiplatelet therapy; upper gastrointestinal tract; bleeding; mortality

  • Open Access

    Clinical Efficacy and Safety of Endoscopic Treatment of Gastrointestinal Stromal Tumors in the Stomach

    by Moon Kyung Joo, Jong-Jae Park, Yeon Ho Lee, Beom Jae Lee, Seong Min Kim, Won Shik Kim, Ah Young Yoo, Hoon Jai Chun, Sang Woo Lee

    Moon Kyung Joo, Jong-Jae Park, Yeon Ho Lee, Beom Jae Lee, Seong Min Kim, Won Shik Kim, Ah Young Yoo, Hoon Jai Chun, and Sang Woo Lee. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl210454


  • Open Access

    High Expression of Claudin-4 Is Associated with Synchronous Tumors in Patients with Early Gastric Cancer

    by Won Shik Kim, Hayeon Kim, Moon Kyung Joo, Byung Il Choi, Ah Young Yoo, Jong-Jae Park, Beom Jae Lee, Seung Han Kim, Hoon Jai Chun

    Claudin (CLDN) is a tight junction protein found in human epithelial cells and its altered expression is known to be associated with the progression of gastric cancer. We aimed to investigate the differential expression of CLDN-4 in early gastric cancer (EGC) according to its clinicopathological characteristics. We enrolled 53 patients with EGC who underwent surgical gastric resection from January 2007 to December 2018. The staining intensity of the tumor cells was scored as 0–3, and the percentage of staining was scored as 0–5; high expression was defined if the intensity plus percentage score was 7 or 8, and low expression was defined if the score was 0–6. Among the 53 patients, 16 (30.2%) showed low CLDN-4 expression, while 37 (69.8%) had high CLDN-4 expression. High CLDN-4 expression was significantly associated with intestinal-type EGC (low: 12.5% vs. high: 56.8%, p = 0.003), open-type atrophic change (low: 60.0% vs. high: 90.9%, p = 0.011), and the presence of synchronous tumors (0 vs. 32.4%, p = 0.010), and all 12 EGCs with synchronous tumors showed high CLDN-4 expression. However, expression of CLDN-3, a typical intestinal phenotype CLDN, was neither correlated with CLDN-4 expression nor associated with synchronous tumors. Taken together, high CLDN-4 expression may be considered as an auxiliary tool for screening synchronous tumors in patients with EGC.